Scoop: Eli Lil­ly and AC Im­mune qui­et­ly scrapped Alzheimer’s stud­ies for the cen­ter­piece of $2B deal months ago

In its quar­ter­ly earn­ings re­port Tues­day, Eli Lil­ly dis­closed it ceased de­vel­op­ment of an in-house, an­ti-tau Alzheimer’s pro­gram af­ter it missed the pri­ma­ry end­point in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER